Biomea Fusion, Inc. (BMEA)
2.03
+0.12
(+6.28%)
USD |
NASDAQ |
Sep 04, 16:00
2.03
0.00 (0.00%)
Pre-Market: 20:00
Biomea Fusion Enterprise Value : 112.83M for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | 112.83M |
| September 03, 2026 | 104.13M |
| September 02, 2026 | 105.94M |
| September 01, 2026 | 96.16M |
| August 31, 2026 | 87.46M |
| August 28, 2026 | 91.08M |
| August 27, 2026 | 87.46M |
| August 26, 2026 | 89.63M |
| August 25, 2026 | 91.08M |
| August 24, 2026 | 80.93M |
| August 21, 2026 | 64.99M |
| August 20, 2026 | 64.26M |
| August 19, 2026 | 66.44M |
| August 18, 2026 | 63.54M |
| August 17, 2026 | 63.54M |
| August 14, 2026 | 61.36M |
| August 13, 2026 | 58.46M |
| August 12, 2026 | 58.46M |
| August 11, 2026 | 59.19M |
| August 10, 2026 | 57.74M |
| August 07, 2026 | 57.01M |
| August 06, 2026 | 56.29M |
| August 05, 2026 | 57.01M |
| August 04, 2026 | 54.84M |
| August 03, 2026 | 52.66M |
| Date | Value |
|---|---|
| July 31, 2026 | 50.49M |
| July 30, 2026 | 54.11M |
| July 29, 2026 | 54.11M |
| July 28, 2026 | 56.29M |
| July 27, 2026 | 57.01M |
| July 24, 2026 | 56.29M |
| July 23, 2026 | 57.01M |
| July 22, 2026 | 59.19M |
| July 21, 2026 | 62.09M |
| July 20, 2026 | 60.64M |
| July 17, 2026 | 58.46M |
| July 16, 2026 | 57.01M |
| July 15, 2026 | 59.19M |
| July 14, 2026 | 59.19M |
| July 13, 2026 | 62.09M |
| July 10, 2026 | 61.36M |
| July 09, 2026 | 60.64M |
| July 08, 2026 | 59.91M |
| July 07, 2026 | 67.16M |
| July 06, 2026 | 65.71M |
| July 02, 2026 | 67.89M |
| July 01, 2026 | 64.26M |
| June 30, 2026 | 72.24M |
| June 29, 2026 | 56.67M |
| June 26, 2026 | 51.61M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| REGENXBIO, Inc. | 628.95M |
| ACADIA Pharmaceuticals, Inc. | 3.941B |
| Alnylam Pharmaceuticals, Inc. | 35.27B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.328M |
| Total Expenses (Quarterly) | 8.328M |
| EPS Diluted (Quarterly) | -0.1151 |
| Earnings Yield | -24.49% |
| Normalized Earnings Yield | -34.37 |